Abstract
We conducted a non-randomized, rater-blind study to safely determine the lowest effective neuroleptic dosage in older psychotic patients and to evaluate the clinical, neuropsychological, and psychosocial effects of neuroleptic dosage reduction. Twenty-seven carefully selected patients with schizophrenia and related psychotic disorders over the age of 45 had their dosage tapered by 25% each month to determine their lowest effective dosage. These patients were compared with patients similar in age, gender, and education who were currently off neuroleptics (n = 19) or maintained on neuroleptics (n = 22). All groups were followed for 11 months. Over the follow-up period, 29% of patients in the taper group, 8% of neuroleptic-free patients, and 0% of patients in the maintenance group experienced some increase in psychopathology, although there was no significant change in mean PANSS score in any group, and no patient required hospitalization. Patients in the taper group were maintained on approximately 60% of their original neuroleptic dosage after restabilization. Extrapyramidal symptoms continued to improve over time in the taper group. Neuropsychological testing did not change significantly over time except for those in the taper ...Continue Reading
References
Dec 1, 1975·The American Journal of Psychiatry·J M Davis
Jun 1, 1977·Archives of General Psychiatry·H E SpohnL Coyne
May 1, 1976·The British Journal of Psychiatry : the Journal of Mental Science·P AndrewsR P Snaith
Apr 1, 1991·The Journal of Nervous and Mental Disease·P E Ruskin, G Nyman
Dec 1, 1990·The Gerontologist·C I Cohen
Jul 1, 1989·Biological Psychiatry·W M GlazerG R Heninger
Jan 1, 1988·Schizophrenia Bulletin·J Angst
Jan 1, 1986·Psychopharmacology Bulletin·J A LiebermanJ Ramos-Lorenzi
Jun 1, 1987·The American Journal of Psychiatry·C M HardingA Breier
Jun 1, 1987·The American Journal of Psychiatry·C M HardingA Breier
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Mar 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·R Prudo, H M Blum
Jan 1, 1967·Psychopharmacologia·M H OrzackH Freeman
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Feb 1, 1981·The American Journal of Psychiatry·W A Brown, T Laughren
Jan 1, 1981·Psychopharmacology·K J ZanderM Ackenheil
Jan 1, 1980·Schizophrenia Bulletin·G HuberM Linz
Jan 1, 1980·Schizophrenia Bulletin·L Ciompi
Apr 1, 1993·Biological Psychiatry·L J SeidmanM T Tsuang
Jul 31, 1996·Psychiatry Research·T L PattersonD V Jeste
Citations
Jan 1, 1997·New Directions for Mental Health Services·D V Jeste, F S McClure
Oct 28, 1999·Biological Psychiatry·D V JesteM J Harris
Dec 13, 2003·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Gail KuslanskyRichard B Lipton
Jun 17, 2003·Journal of the American Medical Directors Association·Richard J Goldberg
Jun 17, 2003·Journal of the American Medical Directors Association·Richard J Goldberg
Mar 10, 2001·Drugs & Aging·M J ByerlyE Lescouflair
Nov 26, 2011·Drugs & Aging·Takefumi SuzukiDavid C Mamo
Apr 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Andrei SzökeMarion Leboyer
May 28, 2010·International Review of Psychiatry·Sami Yamin, Krishna Vaddadi
Jan 27, 1999·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·D V JesteJ Lacro
Aug 26, 2016·Psychopharmacology·Gagan FervahaAriel Graff-Guerrero
May 4, 2004·Biological Psychiatry·Aaron L Mishara, Terry E Goldberg
Nov 18, 2003·International Journal of Geriatric Psychiatry·J S KennedyA Breier
Nov 27, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideaki TaniHiroyoshi Takeuchi
Oct 31, 2002·International Journal of Geriatric Psychiatry·David C MamoDilip V Jeste
Mar 3, 2020·Schizophrenia Bulletin·Jan P A M BogersLieuwe de Haan